Annual report pursuant to Section 13 and 15(d)

Collaborative, Licensing and Other Arrangements (Details)

v2.4.0.8
Collaborative, Licensing and Other Arrangements (Details)
12 Months Ended 36 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 3 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended
Dec. 31, 2013
USD ($)
Milestone
Dec. 31, 2012
USD ($)
Dec. 31, 2011
USD ($)
Dec. 31, 2013
Milestone
Dec. 31, 2013
License Arrangement [Member]
License
Dec. 31, 2013
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
Dec. 31, 2012
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
Dec. 31, 2011
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
Oct. 31, 2011
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
Dec. 31, 2013
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
Dec. 31, 2012
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
Dec. 31, 2011
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
Dec. 31, 2010
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
Dec. 31, 2009
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
Sep. 30, 2008
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
Dec. 31, 2012
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 3 [Member]
USD ($)
Jul. 31, 2006
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 3 [Member]
USD ($)
Dec. 31, 2007
Pfizer Inc. [Member]
License Arrangement [Member]
USD ($)
Jan. 31, 2011
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
Jan. 31, 2011
Collaborative Arrangement [Member]
Servier [Member]
EUR (€)
Dec. 31, 2013
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
Dec. 31, 2012
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
Dec. 31, 2011
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
Dec. 31, 2013
Collaborative Arrangement [Member]
Servier [Member]
Sales And Development Milestones [Member]
USD ($)
Dec. 31, 2010
Collaborative Arrangement [Member]
Servier [Member]
Up-front Payment Arrangement [Member]
USD ($)
Sep. 30, 2010
Collaborative Arrangement [Member]
Servier - U.S. Perindopril Franchise [Member]
USD ($)
Dec. 31, 2013
Collaborative Arrangement [Member]
Servier - U.S. Perindopril Franchise [Member]
Product
Feb. 28, 2009
Collaborative Arrangement [Member]
Takeda [Member]
Nov. 30, 2006
Collaborative Arrangement [Member]
Takeda [Member]
Dec. 31, 2013
Collaborative Arrangement [Member]
Takeda [Member]
USD ($)
Dec. 31, 2012
Collaborative Arrangement [Member]
Takeda [Member]
USD ($)
Dec. 31, 2011
Collaborative Arrangement [Member]
Takeda [Member]
USD ($)
Dec. 31, 2013
Collaborative Arrangement [Member]
Takeda [Member]
Development Milestone [Member]
USD ($)
Feb. 28, 2009
Collaborative Arrangement [Member]
Takeda [Member]
Sales Milestone [Member]
USD ($)
Nov. 30, 2006
Collaborative Arrangement [Member]
Takeda [Member]
Sales Milestone [Member]
USD ($)
Nov. 30, 2008
Collaborative Arrangement [Member]
Novartis [Member]
USD ($)
Dec. 31, 2013
Collaborative Arrangement [Member]
Novartis [Member]
USD ($)
Nov. 30, 2008
Collaborative Arrangement [Member]
Novartis [Member]
Development Milestone [Member]
USD ($)
Product
Dec. 31, 2013
Collaborative Arrangement [Member]
Pfizer Inc. [Member]
Sales Milestone [Member]
USD ($)
Jan. 31, 2014
Non-arrangement Transactions [Member]
Pfizer Inc. [Member]
Development Milestone [Member]
USD ($)
Dec. 31, 2011
Non-arrangement Transactions [Member]
Pfizer Inc. [Member]
Development Milestone [Member]
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                                                                  
Deferred revenue, current                                                 $ 15,000,000                                
Non-refundable upfront payment received                                     15,000,000                                            
Period for recognizing deferred revenue                                         8 months                                        
Proceeds from loan                                     19,500,000 15,000,000                                          
Total contract amount awarded                 28,000,000 3,000,000         64,800,000   16,300,000                                                
Contractual term           5 years       3 years                                                              
Increase in deferred revenue                       900,000   1,100,000   2,000,000                                                  
Recognition of deferred revenue           4,700,000 2,500,000 100,000   4,400,000 6,600,000 18,600,000 21,200,000     2,000,000                           100,000 1,200,000 2,000,000                  
Future initial research and development expenses to be funded by counterparty                                         50,000,000                                        
Future other expenses to be funded by counterparty (in hundredths)                                         50.00%                                        
Licensing and collaboration agreement revenue 11,028,000 5,727,000 17,991,000                                   13,600,000 14,500,000 34,200,000                                    
Future milestone payments, maximum                                               488,000,000                   3,250,000 19,000,000     14,000,000      
Future milestone payments, repurchase option not exercised, maximum                                               827,000,000                                  
Number of fixed-dose combination product candidates included in a portfolio of antihypertensive products from Servier                                                     3                            
License fees paid                                                   1,500,000                              
Future milestone payments with each additional future qualifying product candidate development, maximum                                                                 20,750,000               1,700,000
Royalty right expiration period                                                       10 years 13 years 6 months             20 years          
Proceeds from collaborators                                                                       6,200,000          
Reduction in debt under restructured agreement                                                                       7,500,000          
Number of ongoing product programs with potential royalty right milestone payments                                                                           2      
Maximum borrowing capacity under agreement                                                                         50,000,000        
Research and development expenses funded through loan facility, maximum (in hundredths)                                                                         75.00%        
Additional future milestone payments                                                                             15,200,000    
Number of licenses granted, minimum         60                                                                        
Proceeds from license fees received                                   30,000,000                                              
Number of undisclosed product candidates with milestone payments received 12     10                                                                          
Percentage of milestone received                                                                               25.00%  
Milestone received under the collaboration agreement                                                                               7,000,000  
Repayment of debt                                                                               $ 1,750,000  
Euro to US Dollar exchange rates 1.3766 1.3766   1.3766